Genesis Capital Celebrates with Over 30 Portfolio Companies Recognized in VB100’s '2026 Future Healthcare Top 100' Awards, Garnering Multiple Honors
IMPACT Therapeutics
Targeted Anti-Cancer Innovative Drug Developer
Pulnovo Medical
Developer of Medical Devices in the Field of Pulmonary Hypertension Treatment
APACTRON
Proton Therapy Equipment R&D and Manufacturer
Juncell Therapeutics
Solid Tumor Cell Therapy Developer
Click on the "blue words" above to follow more exciting content.
Recently,The Results of the 10th Future Healthcare 100 Strong Rankings by Arterial Network Are Grandly Revealed.
Yuan BioVentures Partners with 31 Portfolio Companies Again to Rank on This Year's Top 100 List. At the same time, with professional investment capabilities and outstanding investment performance in the medical field,Yuansheng Ventures Honored as "Top 50 Value Investors and Service Providers in China's Healthcare Industry"”。
Top 50 List of Innovative Strength Among Listed Companies
Ascentage Pharma
Kintor Pharmaceuticals
Top 50 List of Overseas Expansion Power of Listed Companies
United Imaging Healthcare
Top 100 List of Innovative Devices and Intelligent Manufacturing
United Imaging IntelligenceTop 100 Innovative Pharmaceuticals and Biologics
Ark BioTop 100 in Innovative Health Services and Industrial Chain Services
Giant Yi Technology
Top 50 Companies with the Most Investment Value in the Healthcare Industry
Listed Company: IMPACT Therapeutics
Non-listed companies: Pulnovo Medical, RuiPu ChenChuang, ZhiRan Medical
Top 50 Most Innovative Products and Technologies in China's Healthcare Industry
APACTRON
ANTAIKANGCHENG
Lancet Robot
StrongLink Innovation
Ascentage Pharma
Juncell Therapeutics Founder, CEO & CTO Jinhu Jun
END
About YuanSheng Ventures
Yuansheng Venture CapitalIs an investment institution focused on the early and growth-stage healthcare sector, based in Suzhou bioBAY with a global reach. It has already invested in over 200 outstanding companies in the life sciences field, spanning four major areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, as well as future medical technologies. These investments have yielded substantial returns, with 21 companies going public on capital markets such as the Hong Kong Stock Exchange and the STAR Market. OrbiMed China has been repeatedly ranked among the top 10 venture capital funds in China's healthcare sector and recognized as one of the most active healthcare investment institutions in China. With a team of seasoned professional investors and a world-class scientific advisory board, OrbiMed China boasts extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry. Leveraging its expertise, focus, and abundant industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.
